Suppr超能文献

继发于补体因子H自身抗体的溶血尿毒综合征的临床谱。

The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies.

作者信息

Kim Jon Jin, McCulloch Mignon, Marks Stephen D, Waters Aoife, Noone Damien

出版信息

Clin Nephrol. 2015 Jan;83(1):49-56. doi: 10.5414/CN107777.

Abstract

BACKGROUND

Atypical hemolytic uremic syndrome (aHUS) is associated with significant mortality, progression to end-stage renal disease and recurrence post transplantation. The deficiency of CFHR plasma proteins and autoantibody-positive hemolytic uremic syndrome (DEAP-HUS) has a more favorable outcome. Guidelines suggest plasma therapy be initiated within 24 hours of presentation of aHUS. Presentation of aHUS, particularly, DEAP-HUS is associated with a diarrheal prodrome in up to 53% of patients and initiation of appropriate therapies is frequently delayed.

CASES

We report on 3 patients with DEAP-HUS, who presented with a diarrheal prodrome that delayed diagnosis and initiation of plasma therapy past the 24-hour window recommended. C3 was low in 2 cases at presentation. All patients had positive complement factor H (CFH) autoantibodies. Despite delay in initiating plasma therapy, all 3 cases remitted with restoration of normal renal function following initial presentation. One patient had a relapse but responded to further plasma exchange and immunosuppression. The remaining 2 patients were relapse-free without maintenance immunosuppression.

CONCLUSION

Our cases highlight the complexity of diagnosing DEAP-HUS due to the common occurrence of diarrhea in the prodromal phase and the subsequent delay in initiating of plasma therapy. We therefore advocate a low threshold for testing CFH autoantibodies in ambiguous cases where there is no history of bloody diarrhea or Shiga-toxin exposure.

摘要

背景

非典型溶血性尿毒症综合征(aHUS)与显著的死亡率、进展至终末期肾病以及移植后复发相关。补体因子H相关血浆蛋白缺乏和自身抗体阳性溶血性尿毒症综合征(DEAP-HUS)的预后较好。指南建议在aHUS出现后24小时内开始血浆治疗。aHUS,尤其是DEAP-HUS,在高达53%的患者中与腹泻前驱症状相关,且适当治疗的启动经常延迟。

病例

我们报告了3例DEAP-HUS患者,他们出现腹泻前驱症状,导致诊断和血浆治疗的启动延迟至超过推荐的24小时窗口期。2例患者就诊时C3水平较低。所有患者的补体因子H(CFH)自身抗体均为阳性。尽管血浆治疗启动延迟,但所有3例患者在初次就诊后肾功能恢复正常,病情缓解。1例患者复发,但对进一步的血浆置换和免疫抑制治疗有反应。其余2例患者未复发,无需维持免疫抑制治疗。

结论

我们的病例凸显了由于前驱期腹泻常见以及随后血浆治疗启动延迟,导致DEAP-HUS诊断的复杂性。因此,我们主张对于无血性腹泻或志贺毒素暴露史的疑似病例,应降低检测CFH自身抗体的阈值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验